News | Henry Ford Hospital | April 27, 2023

Henry Ford Health Cardiologists First in Michigan to Use Heart Recovery Technology

Novel heart pump provides hope for patients with life-threatening heart conditions 

The platform, EchoGo Amyloidosis, uses artificial intelligence to analyze echocardiograms and detect the presence of cardiac amyloidosis, a condition caused by deposits of abnormal proteins in the heart tissue, using only a single commonly acquired ultrasound view of the heart.

The Impella RP Flex with SmartAssist Pump. Courtesy of Abiomed 


April 27, 2023 — Interventional cardiologists at Henry Ford Health are the first in Michigan to treat a patient using the Impella RP Flex with SmartAssist, one of the world’s smallest heart pumps. 

The innovative pump, which provides temporary right heart mechanical circulatory support, allows Henry Ford Health physicians provide more comprehensive and advanced care options to patients in Michigan experiencing acute right heart failure. 

“Henry Ford Health is recognized as the leading provider of cardiovascular care in our region and beyond,” said Khaldoon Alaswad, M.D., an interventional cardiologist and medical director of the Cardiac Catheterization Laboratory at Henry Ford Hospital. “The new heart pump provides our physicians an innovative tool to treat patients experiencing right heart failure.” 

The Impella RP Flex technology received U.S. FDA pre-market approval in October 2022 as safe and effective to treat acute right heart failure or decompensation for up to 14 days following left ventricular assist device implantation, myocardial infarction, heart transplant or open-heart surgery. The pump is implanted via the internal jugular vein, which enables patient mobility, and its dual-sensor technology is designed to optimize patient management. 

“The heart pump’s novel technology allows us to treat right heart failure more effectively,” said Akshay Khandelwal, M.D., MBA, an interventional cardiologist and associate division head of Cardiology at Henry Ford Health. “By allowing a patient’s own heart to rest and recover, we can help improve their quality of life.” 

Henry Ford Health Heart & Vascular teams specialize in diagnosing and treating cardiovascular conditions using minimally invasive techniques. Many of these procedures take place in cardiac catheterization labs. The cardiac cath lab is a special examination room featuring state-of-the-art equipment and specially trained staff who carry out procedures using catheters to access patients’ hearts and surrounding structures through tiny incisions. Henry Ford Hospital was also first in Michigan to use the radial approach technique to access the heart using radial artery in patients’ wrists, allowing most patients to go home the same day as their procedure. 

Globally, more than 250,000 patients have benefited from the Impella heart pump support, developed by Abiomed, a medical device technology company based in Massachusetts. 

For more information: henryford.com/services/heart-and-vascular  

 

Related Impella Content:  


VIDEO: Demonstration of Abiomed Impella ECP 9 French Transcatheter Ventricular Assist Device  


VIDEO: Abiomed Highlights Trends and New Technology in Hemodynamic Support  


FDA Approves First-in-Human Trial of Impella ECP World’s Smallest Heart Pump  


VIDEO: Demonstration of the Impella Percutaneous Hemodynamic Support Device  


VIDEO: Tufts Uses a Hemodynamic Support Algorithm to Determine What Devices to Use — Interview with Navin Kapur, M.D.  


Photo Gallery of the Abiomed Impella Production Line  


VIDEO: Door-to-Unloading (DTU) Trial May Change STEMI Care — Interview with Navin Kapur, M.D.  


VIDEO: Hemodynamic Support Protocols at Henry Ford Hospital — Interview with William O'Neill, M.D.  


Related Content

News | Heart Failure

April 16, 2024 — Each year more than 500,000 Americans undergo percutaneous coronary intervention, or PCI, a minimally ...

Home April 16, 2024
Home
News | Heart Failure

April 12, 2024 — University of Virginia School of Medicine researchers have discovered a gene on the Y chromosome that ...

Home April 12, 2024
Home
News | Heart Failure

April 2, 2024 — People who use e-cigarettes are significantly more likely to develop heart failure compared with those ...

Home April 02, 2024
Home
News | Heart Failure

March 29, 2024 — V-Wave announced it will present late-breaking data from its RELIEVE-HF pivotal trial at the American ...

Home March 29, 2024
Home
News | Heart Failure

March 25, 2024 — A team of engineers led by the University of Massachusetts Amherst and including colleagues from the ...

Home March 25, 2024
Home
News | Heart Failure

March 15, 2024 — BioCardia, Inc. , a biotechnology company focused on advancing late-stage cell therapy interventions ...

Home March 15, 2024
Home
News | Heart Failure

March 15, 2024 — BioCardia, Inc., a biotechnology company focused on advancing late-stage cell therapy interventions for ...

Home March 15, 2024
Home
News | Heart Failure

March 13, 2024 — BioCardia, Inc., a developer of cellular and cell-derived therapeutics for the treatment of ...

Home March 13, 2024
Home
News | Heart Failure

March 8, 2024 — The Texas Heart Institute, Georgia Institute of Technology (Georgia Tech), North Carolina State ...

Home March 08, 2024
Home
News | Heart Failure

March 5, 2024 — FIRE1 announced that it has completed patient enrollment in the U.S. Early Feasibility Study (FUTURE-HF2 ...

Home March 05, 2024
Home
Subscribe Now